Danish Biotech Stock News

Vestas Wind Systems heads into this earnings season with the stock at DKK211.8 after a strong run over the past week and quarter. The market has already priced in optimism. The question now is whether the latest numbers justify that confidence. The headline from Q2 is clear. Revenue reached €4.7b and the EBIT margin before special items came in at 9.4%, helped by a strong performance in Power Solutions and a higher full year EBIT margin guidance range of 7% to 9%. For a capital intensive wind...

When ships pay up to US$4 million just to jump the queue at the Panama Canal, it is a signal that global trade routes are under real strain and that money is being made and lost in unexpected corners of the market. That kind of stress can reshape pricing power, contract terms, and customer relationships. This article walks through three freight forwarding and 3PL stocks that are closely tied to this story and explains how the same news can create very different risk and reward profiles for...

Demant walked into this earnings day with momentum on its side. The stock is up about 22% over the past three months and trading near DKK288.6, helped by a P/E below key hearing care peers despite a strong run. The headline from this report is not the growth story that many investors were leaning on. It is the squeeze in profitability. Net profit margins over the last year sit near 10.3%, lower than the prior year, which jars with a share price that had been pricing in cleaner earnings...

European equities have recently experienced a boost, with the pan-European STOXX Europe 600 Index climbing 1.70% due to improved risk appetite and resilient earnings, despite ongoing geopolitical uncertainties. In this environment of cautious optimism, identifying undervalued stocks can be a strategic move for investors seeking opportunities that are priced below their estimated worth.

Geopolitics, shifting fiscal policies and fresh regulation are quietly reshaping where capital flows next, and many investors only notice once prices have already moved. This mix of pressure and policy focus on sustainable economic development is putting a spotlight on companies tied to cleaner energy and infrastructure. This article walks through three stocks from our Global Sustainable Infrastructure and Clean Energy Leaders screener that appear particularly exposed to these latest...

The market had ISS sitting quietly at DKK285 going into these H1 numbers, with the stock barely moving over the past week. The earnings story is louder than the price action. Revenue for the trailing twelve months stands at DKK87.8b and net income is DKK2.8b, which keeps the net margin at about 3.2%. The key tension is that investors see a facilities services business with modest profitability and a high debt load, yet trading on a P/E of 16x while peers trade on much higher multiples. That...

NTG Nordic Transport Group stock comes into this earnings print with strong recent momentum, up about 39% over three months and trading at DKK266 at Monday’s close. The market has been rewarding the story. The headline from the quarter is clear for a freight and logistics company. Organic revenue growth in Q2 reached 14.8% and adjusted EBIT for the first half of 2026 rose 23% as NTG tightened full year EBIT guidance to a range of DKK625 to DKK650m. Short term price strength now meets a profit...

Russia’s war in Ukraine has turned European energy into a pressure point again, with supply routes, winter demand and sanctions all back in focus. That mix of risk and rearranged trade flows can quickly change how investors look at European Energy Sector stocks. This article walks through three stocks from our screener that appear positively exposed to the latest news, and explains what makes each one worth a closer look now. The three European energy stocks highlighted below are just a...

It looks like Novo Nordisk A/S ( CPH:NOVO B ) is about to go ex-dividend in the next two days. The ex-dividend date is...

How the latest earnings and guidance update set the tone for Ringkjøbing Landbobank Ringkjøbing Landbobank (CPSE:RILBA) just reported half year 2026 earnings alongside a higher full year net profit outlook, giving investors fresh numbers on profitability, income trends and credit quality. The bank posted net interest income of DKK 1,341.78 million for the half year, compared with DKK 1,411.67 million a year earlier. Net income for the same period was DKK 1,193.57 million, slightly above the...

Quite a few insiders have dramatically grown their holdings in H. Lundbeck A/S ( CPH:HLUN B ) over the past 12 months...

DFDS (CPSE:DFDS) is in focus after announcing that Mathieu Girardin will step down as EVP and Head of the Ferry Division on 14 August 2026. CEO Michael Hansen will take over interim control. See our latest analysis for DFDS. At a share price of DKK130.2, DFDS has seen firm short term momentum, with a 7 day share price return of 4.58% and 30 day return of 11.00%. However, the 3 year total shareholder return is down 41.35%, which points to a longer term reset in investor expectations as...

Novo Nordisk (CPSE:NOVO B) is back in focus after reporting second quarter results that paired GLP-1 driven sales growth and a higher full year outlook with fresh legal, clinical and partnership updates. See our latest analysis for Novo Nordisk. Novo Nordisk’s latest earnings, dividend affirmation and completed buyback come after a mixed share price run, with a 1-day share price return of 3.92% contrasting with a year-to-date share price decline of 7.62% and a 3-year total shareholder return...

Genmab guidance change and recent earnings at a glance Genmab (CPSE:GMAB) has raised its 2026 revenue outlook following second quarter results, alongside regulatory progress in Europe and positive Phase III data for key pipeline drugs that broaden its revenue base beyond DARZALEX. See our latest analysis for Genmab. Genmab’s near term momentum has picked up, with a 6.5% 1 day share price return and 20.5% 90 day share price return, while the 1 year total shareholder return of 44.7% contrasts...

It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...

The latest move in Bavarian Nordic (CPSE:BAVA) stock interest comes after the European Commission approved an extension of the IMVANEX marketing authorization to include children aged 2 to under 12. See our latest analysis for Bavarian Nordic. Despite the positive regulatory news, Bavarian Nordic’s recent share price performance has been weak, with the 90 day share price return down 9.35% and the 1 year total shareholder return down 25.76%, while the 3 year total shareholder return remains...

ChemoMetec (CPSE:CHEMM) has announced a change in financial leadership, with the board appointing Phillip Massie Price as chief financial officer from 3 August 2026, replacing outgoing CFO Kim Nicolajsen. See our latest analysis for ChemoMetec. ChemoMetec’s CFO transition comes after a mixed period for shareholders, with the stock posting a 36.6% 90 day share price return while year to date share price performance is down 36.3%, and the 1 year total shareholder return has declined 12.7%. If...

Investors in Ringkjøbing Landbobank A/S ( CPH:RILBA ) had a good week, as its shares rose 2.9% to close at kr.1,792...

Novo Nordisk stock is back under the microscope after a weak three year share price run, even as its valuation checks screen it as attractively priced on several fronts. Recent setbacks in parts of the drug pipeline have weighed on sentiment, while strong demand for obesity treatments keeps investors focused on what the current price actually implies. The share price has fallen 46.9% over the past three years, which means anyone buying today is doing so after a sizeable reset in market...

What Ørsted’s Old 300 Storage milestone means for the stock Ørsted (CPSE:ORSTED) has brought its Old 300 Storage battery project in Needville, Texas, into commercial operation, connecting 250 MW of storage capacity to the ERCOT grid alongside the existing Old 300 Solar facility. This expansion in U.S. battery energy storage, supplied by Tesla Megapacks and paired with one of the larger U.S. solar projects commissioned in 2024, gives investors fresh context for assessing Ørsted’s role in large...

The market has treated Genmab like a growth biotech with questions attached. The stock sits at DKK2,011 after a strong 90 day run of about 23%, and today’s Q2 print gives investors fresh numbers to test that view. The headline is simple. Genmab just delivered Q2 2026 total revenue of US$1.16b with net income of US$303m and basic earnings per share of US$4.94. That is the core of the story investors will weigh against a higher than peer P/E multiple and the company’s ambitious late stage...

Vestas Wind Systems (CPSE:VWS) has drawn fresh investor attention after appointing Anna Mascolo as President of Northern & Central Europe and Global Offshore, following the retirement of long-serving regional leader Nils de Baar. See our latest analysis for Vestas Wind Systems. The leadership change appears to have come at a time when Vestas Wind Systems' short term momentum has cooled, with a 90 day share price return that declined 9.55%, even as the 1 year total shareholder return is...

As the European market continues to show resilience, with indices like the STOXX Europe 600 hitting new highs driven by robust corporate earnings and a recovery in AI-related stocks, investors are keenly observing growth opportunities. In this environment, companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those most familiar with the business's potential.

Novo Nordisk (CPSE:NOVO B) obtained a Dutch court injunction to block a compounding pharmacy from offering an unapproved semaglutide nasal spray. The ruling protects Novo Nordisk's semaglutide patents and limits compounded GLP-1 drug products that fall outside approved uses in Europe. The decision supports the exclusivity of branded therapies Wegovy, Ozempic and Rybelsus at a time of strong market interest in obesity and diabetes treatments. The case highlights how patent enforcement and...